Techsomed Expands BioTraceIO360 for Enhanced Kidney Treatments
Techsomed's FDA 510(k) Clearance for BioTraceIO360
Techsomed, an innovator in AI-driven solutions for image-guided care, proudly announces its recent achievement of receiving FDA 510(k) clearance to expand its BioTraceIO360 platform. This new approval now includes percutaneous ablation capabilities for soft tissue in the kidney, building on its previously established liver application.
Advancing Multi-Organ Image-Guided Therapy
The advancement of the BioTraceIO360 platform signifies a crucial step towards realizing Techsomed’s vision of a unified, hardware-agnostic image-guided therapy system. This innovative approach aims to standardize minimally invasive procedures throughout the planning, execution, and verification stages. By seamlessly integrating kidney treatment, Techsomed enhances the precision and efficacy of medical interventions.
The Importance of Kidney Cancer Treatment
Kidney cancer diagnoses are alarmingly frequent, affecting approximately 82,000 individuals annually. For selected patients, minimally invasive, image-guided ablation techniques represent a less invasive alternative to traditional surgeries, garnering increasing interest among healthcare providers.
Capabilities of BioTraceIO360
The BioTraceIO360 platform significantly enhances treatment processes by enabling clinicians to:
Plan and Simulate
Healthcare professionals can plan and simulate ablation zones prior to procedures, which maximizes the efficiency and effectiveness of treatment.
Guide and Adapt
During procedures, BioTraceIO360 provides real-time, quantitative feedback, allowing for adaptable, precise guidance.
Verify and Document
Post-procedure, the system facilitates comprehensive verification and documentation of treatment coverage, equipping healthcare providers with the tools needed to ensure consistent patient outcomes.
Dr. Eric Hoffer, an Associate Professor of Radiology, commented on the significance of this FDA clearance, stating, "We're encouraged by Techsomed's new FDA clearance and look forward to expanding our use of its AI-driven image-guided therapy platform. Our interventional radiologists are already seeing value from BioTrace, and this milestone creates even more opportunity to enhance patient care."
Yossi Abu, CEO of Techsomed, remarked, "This clearance is a pivotal step toward making interventional oncology a precise, reproducible science. Extending BioTraceIO360 from liver to kidney lays the foundation for a unified multi-organ platform that gives physicians greater precision, consistency, and confidence."
Availability of BioTraceIO360
BioTraceIO360 is now available in the U.S. for both liver and kidney ablation workflows. Interested parties can access demonstrations and clinical documentation by visiting the official Techsomed website.
About Techsomed
Founded in 2015, Techsomed is an Image-Guided Therapy software company dedicated to advancing AI-powered, hardware-agnostic solutions. The company operates internationally and focuses on unifying the processes of planning, executing, and verifying minimally invasive procedures.
Media Contact
For media inquiries, please reach out to Shira Doron, Marketing Director at Techsomed.
Regulatory Disclaimer
BioTraceIO360 has received U.S. FDA 510(k) clearance for the percutaneous ablation of soft tissue in the liver and kidney. For more detailed information, please refer to the labeling which includes full indications, contraindications, warnings, and instructions for use.
Frequently Asked Questions
What is the significance of FDA clearance for BioTraceIO360?
The FDA clearance allows BioTraceIO360 to be used for kidney ablation, expanding its application beyond liver procedures and enhancing patient treatment options.
How does BioTraceIO360 improve treatment planning?
The platform enables doctors to plan and simulate ablation zones before performing procedures, improving accuracy and outcomes.
What are the main features of the BioTraceIO360 platform?
It allows planning, real-time guidance, and thorough documentation throughout the treatment process, enhancing the usability for medical professionals.
Who is the CEO of Techsomed?
Yossi Abu is the CEO of Techsomed and plays a key role in the company’s innovative developments in medical technology.
Where can I find more information about Techsomed?
More information about their services and products can be found on Techsomed's official website.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.